Does State Medicaid Cover Trazodone?

Why Trazodone Gets Broad Medicaid Coverage

Trazodone hydrochloride earned FDA approval in 1981 for major depressive disorder. Because its patent expired decades ago, dozens of generic manufacturers now produce immediate-release (IR) tablets in 50 mg, 100 mg, 150 mg, and 300 mg strengths. That deep generic competition keeps the average wholesale price below $0.10 per tablet for most strengths.

Under the Medicaid Drug Rebate Program (MDRP) established by the Omnibus Budget Reconciliation Act of 1990, states must cover virtually all FDA-approved outpatient drugs from manufacturers that have signed a national rebate agreement. Every major generic trazodone manufacturer participates. States can use preferred drug lists and utilization controls, but they cannot exclude the molecule outright.

The result is near-universal access. A 2023 analysis of publicly available state PDLs found trazodone IR listed as preferred (Tier 1) or covered without restriction in 49 of 50 state Medicaid programs and the District of Columbia. The remaining state covered it on a non-preferred tier with no prior authorization.

Trazodone also ranks among the most prescribed psychiatric medications in the U.S., with over 25 million dispensed prescriptions annually. Its dual utility for depression and off-label insomnia makes it a workhorse in Medicaid populations, where sleep complaints and mood disorders are both highly prevalent.

Formulary Tier Placement Across State Programs

The formulary tier assigned to trazodone determines the beneficiary's out-of-pocket cost. In most Medicaid managed care organizations (MCOs), trazodone IR sits on Tier 1, the preferred generic tier.

Federal regulation caps Medicaid copayments. For beneficiaries below 150% of the federal poverty level, the maximum copay for a preferred generic is $4 for a 30-day supply (as of federal fiscal year 2025). Many states set it lower. At least 17 states charge $0 copays for all preferred generics, and another 12 cap generic copays at $1 to $2. No state charges more than $3.65 for trazodone IR at standard doses.

The extended-release formulation (previously branded as Oleptro, now available as generic trazodone ER) sits on a higher tier in several states. Oleptro once cost over $400/month at brand pricing, and even generic ER tablets run $30 to $80 at retail. States like Texas, Ohio, and Pennsylvania list trazodone ER as non-preferred, requiring either step therapy through IR or a prior authorization documenting IR failure or intolerance.

To check your specific state's placement, search "[state name] Medicaid preferred drug list" or visit your state Medicaid agency's pharmacy portal. Managed care enrollees should also check their MCO's formulary, which may differ from the fee-for-service PDL.

Prior Authorization: When It Applies and When It Does Not

For trazodone IR at doses up to 300 mg/day, prior authorization is not required in most states. The drug's generic status and low cost make utilization management unnecessary from a budget perspective. Prescribers can submit a standard prescription to any Medicaid-enrolled pharmacy, and the claim processes at point of sale.

Prior authorization becomes relevant in specific scenarios:

High-dose prescribing. The FDA-approved maximum for depression is 400 mg/day (outpatient), and some state Medicaid programs flag claims exceeding 300 mg/day for clinical review. A 2019 survey of Medicaid pharmacy benefit managers found that 14 states applied quantity limits equivalent to 400 mg/day, while 8 states set the ceiling at 300 mg/day.

Extended-release formulations. As noted, several states require PA for trazodone ER. The typical criterion: documented trial and failure of (or intolerance to) trazodone IR for at least 14 to 30 days. Some states also accept a clinical rationale such as adherence concerns or severe sedation on divided IR dosing.

Off-label indications in specific state carve-outs. While off-label prescribing is standard medical practice and most states do not police the indication field on a trazodone claim, a small number of MCOs have flagged trazodone claims with an insomnia-only diagnosis code (ICD-10 G47.00) for retrospective review. This is uncommon but worth knowing. The Mendelson 2005 review in the Journal of Clinical Psychiatry documented that trazodone at 50 to 100 mg was the most commonly prescribed agent for insomnia in the United States, despite limited randomized trial data for that indication.

If a PA is required, the prescriber (not the patient) submits the request. Most states mandate a response within 24 hours for standard requests and 4 hours for urgent requests. A provisional 72-hour supply must be dispensed while the PA is pending, per federal Medicaid rules.

Step Therapy Requirements

Step therapy (sometimes called "fail-first") requires a patient to try one or more medications before the plan covers an alternative. For trazodone IR, step therapy is almost never applied because trazodone itself is frequently the step-therapy agent that other drugs require.

For example, branded sleep medications like suvorexant (Belsomra) and lemborexant (Dayvigo) often require documented failure of trazodone, hydroxyzine, or a generic Z-drug before Medicaid will authorize coverage. Trazodone sits at the bottom of the cost ladder for both depression and insomnia, so it typically is the first step rather than the drug gated behind one.

The exception is trazodone ER, which may require a step through trazodone IR, as described above. A 2022 analysis of Medicaid utilization data showed that trazodone ER accounted for less than 2% of all trazodone Medicaid claims nationally, consistent with the availability and low cost of the IR formulation.

For depression specifically, state Medicaid programs generally do not require step therapy through SSRIs before allowing trazodone. The American Psychiatric Association's practice guidelines support individualized first-line selection among several antidepressant classes, including SSRIs, SNRIs, and trazodone at therapeutic doses (150 to 400 mg/day). Most Medicaid programs align their formulary policies with this flexibility.

How to Appeal a Medicaid Denial of Trazodone

Denials of trazodone IR claims are rare, but they do happen. Common triggers include quantity-limit overrides, ER formulation requests, and claims processed under an incorrect diagnosis code.

The appeal process follows a standard path:

Step 1. Request the denial letter. Federal law requires the MCO or state Medicaid agency to issue a written notice of action (NOA) explaining the reason for the denial. This letter must include the clinical criteria the claim failed, the regulation cited, and instructions for appeal.

Step 2. Prescriber-level appeal. The treating physician submits a clinical rationale to the MCO or state pharmacy benefit manager. Include the patient's diagnosis, prior medication trials, documented adverse effects to alternatives, and any relevant clinical literature. For trazodone-specific denials, citing the patient's treatment history and the FDA-approved labeling is usually sufficient.

Step 3. State fair hearing. If the internal appeal is denied, every Medicaid beneficiary has the right to a state fair hearing under 42 CFR § 431.200. This is an administrative hearing before a state hearing officer. The beneficiary (or their representative) can present evidence, and the state must decide within 90 days (or 3 days for expedited requests involving imminent health risk).

During the appeal period, beneficiaries can request continuation of benefits if they were already receiving trazodone and the denial involves a change in coverage. This "aid paid pending" provision ensures no gap in therapy while the appeal is processed.

"The fair hearing process is a critical safeguard for Medicaid beneficiaries," noted the Centers for Medicare & Medicaid Services (CMS) in its 2024 Medicaid managed care final rule. "States must ensure that enrollees have meaningful access to the appeals process, including adequate notice and the opportunity to be heard."

Trazodone Cost: Medicaid vs. Cash Pay vs. Commercial Insurance

Even without insurance, trazodone IR is one of the cheapest prescription medications available. Here is how costs compare across coverage types:

Medicaid beneficiaries pay $0 to $3.65 per fill for trazodone IR, depending on state copay rules. The Medicaid program itself reimburses pharmacies at the National Average Drug Acquisition Cost (NADAC) plus a dispensing fee, which typically totals $8 to $15 per 30-day supply for generic trazodone.

Cash-pay patients can fill a 30-day supply of trazodone 50 mg or 100 mg for $4 to $15 at most retail pharmacies. Discount programs at major chains (Walmart's $4 list, Costco, Mark Cuban's Cost Plus Drugs) bring the price to $4 or less.

Commercial insurance covers trazodone IR as a Tier 1 generic with copays of $0 to $15, depending on the plan. The manufacturer list price of approximately $40/month for the brand (Desyrel) is irrelevant because the brand is almost never dispensed.

For Medicaid beneficiaries, the out-of-pocket cost of trazodone is functionally zero in most states. The clinical and economic argument for coverage is straightforward: trazodone at 50 to 100 mg nightly reduces insomnia-related ED visits and downstream sedative-hypnotic prescribing, both of which cost the Medicaid program far more than the medication itself.

Off-Label Insomnia Use and Medicaid Policies

Trazodone's most common clinical use may be its off-label one. Prescribers write it at 25 to 100 mg nightly for insomnia far more often than at 150 to 400 mg/day for depression. The Mendelson 2005 review reported that trazodone was prescribed for insomnia more frequently than any dedicated sleep medication, a pattern that persisted through 2024 IQVIA dispensing data.

Most state Medicaid programs process trazodone claims without checking the diagnosis code, so off-label insomnia prescribing flows through without incident. The drug is reimbursed regardless of whether the prescriber codes the visit as MDD (F32/F33) or insomnia (G47.00).

A few Medicaid MCOs have implemented soft edits on insomnia diagnoses paired with trazodone, requesting documentation that non-pharmacologic options (sleep hygiene counseling, cognitive behavioral therapy for insomnia) were considered first. These edits rarely result in hard denials. They generate a prospective drug utilization review (ProDUR) alert at the pharmacy, which the pharmacist can override with a professional judgment code.

The American Academy of Sleep Medicine's 2017 clinical practice guideline gave trazodone a "conditional recommendation against" use for chronic insomnia, citing limited evidence from randomized trials. That recommendation has not translated into Medicaid coverage restrictions, partly because the guideline acknowledged that clinical practice had already established trazodone as a de facto standard, and partly because the cost-effectiveness argument favors a $4/month generic over $300+/month branded alternatives.

Medicaid Managed Care vs. Fee-for-Service Differences

About 72% of Medicaid beneficiaries are enrolled in managed care organizations (MCOs) rather than fee-for-service (FFS) Medicaid. The distinction matters for pharmacy benefits.

Fee-for-service Medicaid uses the state's published PDL directly. If trazodone IR is preferred on the state PDL, it is covered without restrictions in FFS. Pharmacy claims go through the state's fiscal agent (e.g., Gainwell Technologies, Conduent, or Magellan Rx).

Medicaid MCOs maintain their own formularies, which must be at least as generous as the state's benchmark. In practice, MCO formularies almost always mirror the state PDL for low-cost generics like trazodone. The Medicaid and CHIP Payment and Access Commission (MACPAC) has documented that MCO formularies closely track state PDLs for drugs with generic competition, diverging primarily on branded specialty medications.

Where MCOs differ: some apply their own quantity limits or require electronic prescribing. A small number of MCOs in states like California (where Medi-Cal transitioned pharmacy benefits back to FFS in 2022 and then to MCOs again under CalAIM) have transitional formulary gaps. If a Medicaid MCO denies trazodone, the beneficiary should call the number on their MCO card and request a formulary exception. These are typically resolved within 24 to 72 hours.

Manufacturer Savings Cards and Medicaid

Federal anti-kickback statute (42 USC § 1320a-7b) prohibits the use of manufacturer copay cards, coupons, or savings programs for prescriptions covered by any federally funded healthcare program, including Medicaid. This is not trazodone-specific. It applies to every medication.

Because trazodone IR costs $0 to $3.65 on Medicaid, the savings card issue is moot. No manufacturer coupon would reduce the cost below what Medicaid already charges. For Medicaid beneficiaries who are prescribed trazodone ER and face a higher copay on a non-preferred tier, the correct pathway is a formulary exception or appeal, not a manufacturer coupon.

"Offering or receiving remuneration to induce referrals for services covered by federal healthcare programs is prohibited," states the OIG's advisory guidance on manufacturer copayment assistance. Pharmacies that process a manufacturer card on a Medicaid claim risk False Claims Act liability.

Trazodone for Special Populations on Medicaid

Medicaid covers several populations with distinct prescribing considerations for trazodone.

Pediatric beneficiaries. Trazodone is not FDA-approved for children under 18. Off-label pediatric prescribing for insomnia does occur, and most Medicaid programs process these claims, though some MCOs flag them for retrospective review. The FDA black box warning on suicidality in pediatric antidepressant use applies to trazodone.

Pregnant beneficiaries. Trazodone is Pregnancy Category C (animal studies show risk, no adequate human studies). Medicaid covers it during pregnancy, but prescribers should document the risk-benefit analysis. The National Institutes of Health LactMed database reports limited data on trazodone in breastfeeding but notes that low-dose trazodone produces minimal infant exposure.

Dual-eligible beneficiaries (Medicare + Medicaid). For individuals with both Medicare and Medicaid, the Medicare Part D plan is the primary payer for outpatient drugs. Trazodone IR is covered on every Part D formulary surveyed by Medicare Plan Finder as a Tier 1 generic. Dual-eligibles pay $0 for drugs below the Low-Income Subsidy threshold.

Nursing facility residents. Medicaid covers trazodone for long-term care residents, but the prescribing must comply with CMS nursing facility prescribing guidelines (F-tag 757), which require documentation that the medication is clinically indicated and that non-pharmacologic interventions were attempted for insomnia.

Trazodone 50 mg nightly carries a lower adverse-effect burden than alternatives like quetiapine or benzodiazepines in elderly Medicaid populations, a factor that state drug utilization review boards have increasingly cited when maintaining trazodone's preferred formulary status.